Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-5.65 Insider Own11.54% Shs Outstand2.02M Perf Week4.17%
Market Cap5.40M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.91M Perf Month-12.59%
Income-8.22M PEG- EPS next Q- Inst Own9.65% Short Float5.71% Perf Quarter-54.95%
Sales0.00M P/S- EPS this Y- Inst Trans-79.66% Short Ratio0.49 Perf Half Y-80.22%
Book/sh6.06 P/B0.41 EPS next Y- ROA-22.60% Short Interest0.11M Perf Year-94.79%
Cash/sh2.28 P/C1.10 EPS next 5Y- ROE-29.12% 52W Range2.00 - 70.50 Perf YTD-67.79%
Dividend Est.- P/FCF- EPS past 5Y67.29% ROI-64.34% 52W High-96.45% Beta2.25
Dividend TTM- Quick Ratio1.17 Sales past 5Y-20.00% Gross Margin- 52W Low25.00% ATR (14)0.27
Dividend Ex-Date- Current Ratio1.17 EPS Y/Y TTM52.05% Oper. Margin0.00% RSI (14)46.78 Volatility9.05% 11.41%
Employees6 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price32.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-3.10% Payout- Rel Volume0.08 Prev Close2.52
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume223.42K Price2.50
SMA204.10% SMA50-16.71% SMA200-82.25% Trades Volume17,989 Change-0.79%
Apr-09-24 08:21AM
Mar-05-24 09:15AM
Feb-13-24 11:45AM
Dec-29-23 12:45PM
Dec-06-23 09:15AM
09:00AM Loading…
Oct-19-23 09:00AM
Oct-04-23 07:30AM
Aug-14-23 08:30AM
Aug-02-23 08:30AM
Jul-31-23 09:00AM
Apr-12-23 08:30AM
Mar-20-23 08:55AM
Mar-08-23 08:30AM
Mar-02-23 08:30AM
Feb-28-23 08:30AM
08:45AM Loading…
Feb-21-23 08:45AM
Dec-06-22 09:40AM
Nov-17-22 08:00AM
Nov-14-22 08:00AM
Sep-20-22 08:00AM
Aug-30-22 08:30AM
Aug-03-22 09:45AM
Jul-29-22 09:19AM
Jul-26-22 07:30AM
Jul-12-22 09:30AM
Jun-21-22 10:30AM
Apr-05-22 09:15AM
Mar-24-22 09:26AM
Feb-23-22 09:15AM
Feb-20-22 08:37AM
09:15AM Loading…
Feb-08-22 09:15AM
Feb-07-22 08:38PM
Jan-05-22 09:15AM
Dec-29-21 09:15AM
Dec-16-21 10:50AM
Dec-01-21 10:05AM
Nov-23-21 09:25AM
Nov-18-21 09:15AM
Nov-16-21 09:25AM
Nov-15-21 09:45AM
Oct-26-21 10:30AM
Oct-19-21 10:30AM
Oct-05-21 10:00AM
Sep-22-21 11:00AM
Sep-13-21 10:00AM
Sep-09-21 10:15AM
Aug-24-21 10:17AM
Aug-23-21 08:47AM
Aug-10-21 02:30PM
Aug-05-21 10:30AM
Jul-27-21 09:15AM
Jul-07-21 09:00AM
Jun-07-21 10:02AM
May-17-21 09:00AM
May-12-21 09:00AM
May-10-21 09:00AM
Apr-28-21 10:13AM
Apr-22-21 09:20AM
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. It focuses on developing and commercializing the MyMD-1 and SUPERA-CBD therapeutic platforms. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune diseases. Supera-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rivard PaulChief Legal OfficerAug 24 '23Buy1.11150,000166,500400,000Aug 24 05:58 PM
Rivard PaulChief Legal OfficerAug 17 '23Buy1.1225,00028,080250,000Aug 18 04:21 PM